Edition:
United Kingdom

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

113.11USD
2:48pm GMT
Change (% chg)

$0.91 (+0.81%)
Prev Close
$112.20
Open
$111.67
Day's High
$113.16
Day's Low
$111.67
Volume
231,161
Avg. Vol
1,012,158
52-wk High
$116.61
52-wk Low
$73.70

Summary

Name Age Since Current Position

David Ricks

50 2017 Chairman of the Board, President, Chief Executive Officer

Joshua Smiley

48 2018 Chief Financial Officer, Senior Vice President

Jan Lundberg

64 2010 Executive Vice President - Science and Technology, President - Lilly Research Laboratories

Aarti Shah

53 2018 Senior Vice President - Information Technology, and Chief Information Officer

Melissa Barnes

50 2013 Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer

Michael Harrington

56 2013 Senior Vice President, General Counsel

Stephen Fry

52 2011 Senior Vice President - Human Resources and Diversity

Enrique Conterno

51 2017 Senior Vice President and President - Lilly Diabetes and President - Lilly USA

Susan Mahony

53 2011 Senior Vice President and President - Lilly Oncology

Johna Norton

51 2017 Senior Vice President - Global Quality

Myles O'Neill

59 2018 Senior Vice President and President - Manufacturing Operations

Leigh Pusey

55 2017 Senior Vice President - Corporate Affairs and Communications

Christi Shaw

51 2017 Senior Vice President and President - Lilly Bio-Medicines

Jeffrey Simmons

50 2008 Senior Vice President and President - Elanco Animal Health

Daniel Skovronsky

44 2018 Senior Vice President - Science and Technology, and President, Lilly Research Laboratories

Alfonso Zulueta

55 2017 Senior Vice President and President, Lilly International

Ellen Marram

71 2013 Lead Independent Director

Ralph Alvarez

62 2009 Independent Director

Katherine Baicker

46 2011 Independent Director

Carolyn Bertozzi

51 2017 Independent Director

Michael Eskew

68 2008 Independent Director

J. Erik Fyrwald

58 2005 Independent Director

R. David Hoover

72 2009 Independent Director

Jamere Jackson

49 2016 Independent Director

William Kaelin

60 2012 Independent Director

Juan Luciano

56 2016 Independent Director

Marschall Runge

63 2013 Independent Director

Kathi Seifert

68 1995 Independent Director

Jackson Tai

67 2013 Independent Director

Biographies

Name Description

David Ricks

Mr. David A. Ricks is Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Ricks was named President and CEO on January 1, 2017, and joined the board at that time. He became Chairman of the Board on June 1, 2017. Mr. Ricks joined Lilly in 1996 and most recently served as president of Lilly Bio-Medicines. He has deep expertise in product development, global sales and marketing, as well as public policy. He has significant global experience in the company's commercial operations.

Joshua Smiley

Mr. Joshua Smiley is Chief Financial Officer, Senior Vice President of the Company. He has served as senior vice president and treasurer of the company since October 2016. Mr. Smiley joined Lilly in 1995 as a financial analyst and has held a broad range of corporate strategy and financial management positions at the company. Before assuming his current position, he served as senior vice president and controller and chief financial officer of Lilly Research Laboratories from 2011 to 2016.

Jan Lundberg

Dr. Jan M. Lundberg Ph.D., is a Executive Vice President - Science and Technology, President - Lilly Research Laboratories of the Company. He has a Ph.D. from Sweden's Karolinska Institute, where he was a professor in the department of pharmacology before moving to industry. Prior to Karolinska, he attended Gustavus Adolphus College in Minnesota and the University of Gothenburg in Sweden. He has been a member of the Swedish Medical Research Council and of the Advisory Board for Drug Approvals at the Swedish Medical Product Agency. In January 2003, he was appointed Honorary Doctor of Pharmacy at Uppsala University. During the last 10 years at AstraZeneca, as head of global discovery research, he was instrumental in delivering 150 drug candidates to the company's pipeline. He had a role in external activities, including in-licensing of projects and technologies, as well as acquisitions of biotech companies. His organization was with both small molecules and biologics. For the past seven years, he has been an executive vice president and member of the senior executive team, reporting to the CEO of AstraZeneca.

Aarti Shah

Melissa Barnes

Ms. Melissa S. Barnes is a Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer of the Company, since January 2013.

Michael Harrington

Mr. Michael J. Harrington is Senior Vice President, General Counsel of the Company. He lead significant efforts during 2013 to develop and implement the "Protect Lilly" program, the company's comprehensive data protection program. Mr. Harrington also served as a trusted advisor to the executive team and has contributed to a strong ethics and compliance tone within the company.

Stephen Fry

Mr. Stephen F. Fry is a Senior Vice President - Human Resources and Diversity of the Company. He was the managing director of Lilly's Australian affiliate from 2004 -- 2007, then served in human resources capacities as executive director for the intercontinental region and Japan until becoming vice president for bio-medicines and emerging markets. He joined Lilly in 1987 as a scientific systems analyst in the company's former Greenfield, Ind. laboratories, moving into human resources in 1992. He assumed a leadership role when he was selected as the director of human resources for Lilly's United Kingdom affiliate in 1998, followed by executive director positions for both Lilly's U.S. affiliate and the pharmaceutical operations area. He has a bachelor's degree in business from the University of Indianapolis.

Enrique Conterno

Mr. Enrique A. Conterno is Senior Vice President and President - Lilly Diabetes and President - Lilly USA of the Company. He became president of the diabetes business unit on November 1, 2009. The business unit, which becomes operational on January 1, 2010, enhances the company’s diabetes focus. Since January 2009, he had served as president of Lilly USA. He is a member of Lilly's operations committee and senior management council. He earned a master's of business administration degree at Duke University in 1992. He earned his bachelor’s degree in mechanical engineering from Case Western Reserve University in 1989. He joined Lilly as a sales representative in 1992. From 1993 to 1995, he held as a financial analyst, marketing associate, and business development manager. In 1996, Conterno became sales and marketing director for the Peru affiliate, and in 1998, he became the sales and marketing director for Lilly's affiliate in Brazil. In 2000, he was named executive director of marketing for the intercontinental region and Japan. He served as president and general manager for Lilly’s operations in Mexico in 2003, and was named vice president of Lilly USA's neuroscience business unit in July 2006. In June 2008, he was named senior vice president of health care professional markets for Lilly USA.

Susan Mahony

Dr. Susan Mahony Ph.D., is a Senior Vice President and President - Lilly Oncology of the Company. She has been Senior Vice President, Human Resources and Diversity (May 2009 – February 2011). Ms. Mahony joined Lilly eight years ago, after a decade in sales and marketing roles in the United Kingdom and Europe for Amgen, Bristol-Myers Squibb, and Schering-Plough. She was named general manager of Lilly Canada in 2008 after roles in global marketing and new product development, including a leadership in the development of Cymbalta(R). She was the Six Sigma leader for Lilly's sales and marketing component. Ms. Mahony received her bachelor's degree and Ph. D. in pharmacy from Aston University in Great Britain, and holds an MBA from the London Business School.

Johna Norton

Myles O'Neill

Leigh Pusey

Ms. Leigh Ann Pusey is Senior Vice President - Corporate Affairs and Communications of the Company. She first joined AIA in December 1996 as senior vice president for public affairs. She then served as chief operating officer and senior vice president of government affairs before being elevated to president and CEO in February 2009, succeeding former Montana governor Marc Racicot and becoming one of the few women to head a major insurance organization. AIA represents more than 325 insurers. Prior to joining AIA, Pusey had been the deputy assistant to President George H.W. Bush for the White House Office of Public Liaison, communications coordinator for U.S. House Speaker Newt Gingrich (R-Ga.), and deputy director of communications for the Republican National Committee.

Christi Shaw

Ms. Christi Shaw is Senior Vice President and President - Lilly Bio-Medicines of the Company. Prior to returning to Lilly, Shaw served as U.S. country head and president of Novartis Pharmaceutical Corporation from 2014 to 2016, and as North American region head of Novartis Oncology from 2010 to 2014.

Jeffrey Simmons

Mr. Jeffrey N. Simmons is a Senior Vice President and President - Elanco Animal Health of the Company, since January 2008.

Daniel Skovronsky

Dr. Daniel M. Skovronsky, M.D. Ph.D. is Senior Vice President - Science and Technology, and President, Lilly Research Laboratories of the Company. Prior to joining the company in 2010, Dr. Skovronsky was CEO and founder of Avid Radiopharmaceutical Inc.

Alfonso Zulueta

Mr. Alfonso Zulueta is Senior Vice President and President, Lilly International of the Company. He received a bachelor's degree in economics from De La Salle University in the Philippines in 1982 and an MBA from the University of Virginia in 1987. In his 25 year career with Lilly, Zulueta has held several sales and marketing leadership positions in the United States before becoming general manager for the Philippines affiliate in 1995. He served as president of Asian operations prior to being promoted in 2008 to his current role as president and general manager of Lilly Japan, the company's second largest market and affiliate behind only the U.S.

Ellen Marram

Ms. Ellen R. Marram is Lead Independent Director of the Company. Ms. Marram is a former CEO with a strong marketing and consumer-brand background. Through her non-profit and private company activities, she has a special focus and expertise in wellness and consumer health. Ms. Marram has extensive corporate governance experience through service on other public company boards in a variety of industries.

Ralph Alvarez

Mr. Ralph Alvarez is Independent Director of the Company. Mr. Alvarez is executive chairman of Skylark Co., Ltd., a restaurant operator in Japan, a position he has held since January 2013. Previously, Mr. Alvarez served as president and chief operating officer of McDonald's Corporation from August 2006 until his retirement in December 2009. He also served as president of McDonald's North America, with responsibility for all the McDonald's restaurants in the U.S. and Canada. Prior to that, he was president of McDonald's USA. Mr. Alvarez joined McDonald's in 1994 and held a variety of leadership roles throughout his career, including chief operations officer and president of the central division, both with McDonald's USA and president of McDonald's Mexico. Prior to joining McDonald's, he held leadership positions at Burger King Corporation and Wendy's International, Inc. Mr. Alvarez serves on the board of directors of Skylark Co., Ltd., Lowe's Companies, Inc., and Dunkin' Brands Group, Inc. Mr. Alvarez also serves on the President's Council, the School of Business Administration Board of Overseers, and the International Advisory Board of the University of Miami. He was previously a member of the boards of McDonald's Corporation and KeyCorp.

Katherine Baicker

Dr. Katherine Baicker, Ph.D. is Independent Director of the Company. She is Professor of Health Economics at the Harvard University School of Public Health, Department of Health Policy and Management; and Research Associate at the National Bureau of Economic Research Dr. Baicker has been a professor of health economics at the Department of Health Policy and Management, School of Public Health, since 2007. From 2005 to 2007, she served as a Senate-confirmed member of the Council of Economic Advisers. From 1998 to 2005, Dr. Baicker was assistant professor and associate professor of economics at Dartmouth College. In 2001 and 2002 she also served as an economist to the Council of Economic Advisers, Executive Office of the President, and in 2003 was a visiting assistant professor at the University of Chicago Harris School of Public Policy. Dr. Baicker is a commissioner of the Medicare Payment Advisory Commission and serves on the Panel of Health Advisers to the Congressional Budget Office. She is a member of the editorial boards of Health Affairs and the Journal of Health Economics, chair of the board of directors of AcademyHealth, editor of the Forum for Health Economics and Policy, and associate editor of the Journal of Economic Perspectives. She is an elected member of the Institute of Medicine.

Carolyn Bertozzi

Dr. Carolyn R. Bertozzi is Independent Director of the Company. She is currently a professor of Chemistry, Chemical and Systems Biology, and Radiology at Stanford University, and an Investigator at the Howard Hughes Medical Institute. From 1996 to 2015, she was a professor of Chemistry and Molecular Biology at the University of California, Berkeley. She holds a bachelors degree in chemistry from Harvard University and a Ph.D. in chemistry from the University of California, Berkeley. Dr. Bertozzi serves on the Public Policy and Compliance Committee and the Science and Technology Committee.

Michael Eskew

Mr. Michael L. Eskew is Independent Director of the Company. Mr. Eskew has CEO experience with UPS, where he established a record of success in managing complex worldwide operations, strategic planning, and building a strong consumer-brand focus. He is an audit committee financial expert, based on his CEO experience and his service on other U.S. company audit committees. He has extensive corporate governance experience through his service on the boards of other companies.

J. Erik Fyrwald

Mr. J. Erik Fyrwald is Independent Director of the Company. He is President and Chief Executive Officer, Univar, Inc. He joined Univar Inc., a distributor of industrial and specialty chemicals and provider of related services, in May 2012 as its president and chief executive officer. In 2008, following a 27-year career at E.I. duPont de Nemours and Company (DuPont), he joined Nalco Company, serving as chairman and chief executive officer until 2011, when Nalco merged with Ecolab Inc. Following the merger, Mr. Fyrwald served as president of Ecolab. From 2003 to 2008, Mr. Fyrwald served as group vice president of the agriculture and nutrition division at DuPont. From 2000 until 2003, he was vice president and general manager of DuPont's nutrition and health business. At DuPont, he held a broad variety of assignments in a number of divisions covering many industries. He has worked in several locations throughout North America and Asia. Mr. Fyrwald serves as a director of the Society of Chemical Industry, Amsted Industries, and the Chicago Public Education Fund, and he is a trustee of the Field Museum of Chicago.

R. David Hoover

Mr. R. David Hoover is Independent Director of the Company. Mr. Hoover has extensive CEO experience at Ball Corporation, with a strong record of leadership in operations and strategy. He has deep financial expertise as a result of his experience as CEO and CFO of Ball. He also has extensive corporate governance experience through his service on other public company boards.

Jamere Jackson

Mr. Jamere Jackson is Independent Director of the Company. He brings to the board significant global financial expertise and strong background in strategic planning, having spent his professional career in a broad range of financial and strategic planning roles. He is an audit committee financial expert, based on his CFO experience and his training as a certified public accountant.

William Kaelin

Dr. William G. Kaelin Jr., M.D., is Independent Director of the Company. Dr. Kaelin is a prominent medical researcher and academician. He has extensive experience at Harvard Medical School, a major medical institution, as well as special expertise in oncology—a key component of Lilly's business. He also has deep expertise in basic science, including mechanisms of drug action, and experience with pharmaceutical discovery research.

Juan Luciano

Mr. Juan Ricardo Luciano is Independent Director of the Company. Mr. Luciano has CEO and global business experience with Archer Daniels Midland Company, where he has established a reputation for strong result-oriented and strategic leadership, as well as many years of global leadership experience at The Dow Chemical Company. He brings to the board a strong technology and operations background, along with expertise in the food and agriculture sectors, an expanding area of focus for Lilly and its Elanco business.

Marschall Runge

Dr. Marschall S. Runge, M.D., Ph.D., is Independent Director of the Company. Dr. Runge brings the unique perspective of a practicing physician who has a broad background in health care, clinical research, and academia. He has extensive experience as a practicing cardiologist, a strong understanding of health care facility systems, and deep expertise in biomedical research and clinical trial design.

Kathi Seifert

Ms. Kathi P. Seifert is Independent Director of the Company. She is a retired senior executive of Kimberly-Clark. She has strong expertise in consumer marketing and brand management, having led sales and marketing for several worldwide brands, with a special focus on consumer health. She has extensive corporate governance experience through her other board positions.

Jackson Tai

Mr. Jackson Peter Tai is Independent Director of the Company. Mr. Tai is a former CEO with extensive experience in international business and finance, and is an audit committee financial expert. He has deep expertise in the Asia-Pacific region, a key growth market for Lilly. He also has broad corporate governance experience from his service on public company boards in the U.S., Europe, and Asia.